Concepedia

Putative biomarkers of vedolizumab resistance and underlying inflammatory pathways involved in IBD

Christoffer Soendergaard, Jakob Benedict Seidelin, Casper Steenholdt, Ole Haagen Nielsen

BMJ Open Gastroenterology · 2018 · 42 citations · 47 references

DOIFull text

Open access

Abstract

Patients with IBD failing vedolizumab induction and anti-TNF therapy have persistent IL-6 pathway activity, which could be a potential alternative treatment target. sCD40L, osteocalcin and the IL-6 pathway activity might be predictors for response to vedolizumab.

References

47

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Stephen B. Hanauer, Brian G. Feagan, Gary R. Lichtenstein et al. · The Lancet · 2002 · 4.1K citations

, , +5

Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis

Paul Rutgeerts, William J. Sandborn, Brian G. Feagan et al. · New England Journal of Medicine · 2005 · 3.8K citations · Full text

Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis

Kenneth W. Schroeder, William J. Tremaine, Duane M. Ilstrup · New England Journal of Medicine · 1987 · 3K citations

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

Brian G. Feagan, Paul Rutgeerts, Bruce E. Sands et al. · New England Journal of Medicine · 2013 · 2.8K citations · Full text

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

William J. Sandborn, Brian G. Feagan, Paul Rutgeerts et al. · New England Journal of Medicine · 2013 · 2.6K citations · Full text